Our work confirms that PML is upregulated in ccRCC (at the mRNA and protein level) in tissues and cell lines, thus implying that previously reported evidence of PML downregulation (Lin et al, 2014) may be due to patients’ selection or use of a specific antibody for immunohistochemical studies. Here, PML is linked to nonpapillary renal cell carcinoma.